The Australian Advantage for early phase clinical studies

360biolabs, a BioAgilytix Company

360biolabs is Australia’s most comprehensive bioanalytical laboratory with extensive range of assay services pharmacokinetic (PK) and pharmacodynamic (PD) endpoints including small molecule and large molecule PK, ADA, NAb, biomarkers (MSD, SIMOA, Luminex, ELISpot), molecular assays and virology, in a single laboratory for all your clinical trial requirements. Our state-of-the-art laboratories in Melbourne and Brisbane, specialise in novel therapeutics, vaccines and diagnostics and a range of modalities. Our global team has laboratories in both the Europe and the United States.

Beyond Drug Development

Beyond Drug Development is a boutique integrated product development consultancy and CRO dedicated to early-stage product development, focusing primarily on advancing innovative products from small to medium biotechnology and pharmaceutical companies worldwide. As an Australian privately owned company, we provide flexible and nimble solutions to match the needs of our clients, whether it is a stand-alone activity or a full suite of services.  The Beyond Collective provides expert support with a team averaging 20 years experience in early phase product development, including preclinical consulting, guiding clients through product development post-discovery into the successful conduct of clinical trials in the Australia region and “Beyond”…

RDI Partners

RDI Partners is an award winning, Australian corporate services business and team of scientists, accounts, lawyers and business executives that deliver a one-stop-shop of fixed cost, professional corporate services that enable non-Australian groups to establish a functional corporate presence in Australia  through which they conduct clinical development activities and benefit from the Australian R&D Tax Incentive.

RDI Partners’ services include entity establishment, full accounting and tax, Australian resident director, company secretarial and public officer, R&D Tax, International Tax structures, transfer pricing analysis and intercompany agreements.

Scientia Clinical Research (SCR)

Scientia Clinical Research (SCR) is the first and only dedicated Phase I clinical trial unit, centrally located in Sydney that operates as a Not For Profit. With the ability to engage participants on a 24/7 basis, our goal is to help sponsors accelerate their development, simplify their Phase I study and generate results that are accepted by all major regulators, including the FDA, EMA, PMDA and NMPA. We conduct approximately 50 clinical trials per year, and we are uniquely positioned to provide biotech sponsors with a high degres of personalised attention. With broad experience across a multitude of study designs, we can reduce study complexity and give your product the best chance for success inthe early phase development stage. Our track record of success for sponsors from around the world and our ability to recruit for even the most complex oncology studies in vulnerable populations sets us apart. Coupled with our capacity to manufacture finished investigational product with our inhouse compounding suite, Scientia is uniquely positioned.